Compared with the clinically used agent doxorubicin, Cys-hMnO2@GOx@EM-CD24 likewise demonstrated therapeutic efficacy; with comparable body-weight trajectories, the nanoplatform delivered superior tumor control (Fig. S8A–C). The gene discussed is CD24; the disease is neoplasm.